Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- AVAV +10%, GSM +4.8%, CAL +3.2%, BOBE +0.5%
M&A news:
- COL +1.7% (cont strength on UTX spec)
Other news:
- MZOR +6.4% (Mazor Robotics and Medtronic (MDT) enter next phase of strategic partnership earlier than planned; triggers $40 mln third tranche investment in Mazor)
- OHGI +5.9% (implements $500,000 secure messaging contract with Hong Kong customer; also announces issuance of stock to Principal Executive Officer Martin Ward as repayment for debt)
- MDCO +5.3% (FDA approved Vabomere for adults with complicated urinary tract infections)
- CUR +3.9% (continued strength after closing +12%)
- FSNN +3.8% (after closing up more than 25% on the day)
- ALIM +3.6% (Alimera Sciences signs a distribution agreement with Horus Pharma; Horus will serve as Alimera's exclusive distributor in France for ILUVIEN )
- JUNO +3.5% (continued strength after KITE/GILD news)
- VSI +3% (Director discloses the purchase of 40k shares at $5.50 )
- IMGN +2% (extending yesterday's move higher on JAZZ news)
- COL +1.7% (cont strength on UTX spec)
- XON +1.4% (continued strength after closing near highs)
- LLY +1% (Eli Lilly and Incyte (INCY) to resubmit the NDA for baricitinib before the end of January)
- SFM +0.9% (CFO disclosed purchase of 7000 shares worth approx $138.6K)
- AN +0.6% (authorized the repurchase of up to an additional $250 million of common stock)
Analyst comments:
- ITCI +8.1% (upgraded to Buy from Neutral at Ladenburg Thalmann)
- OLED +2.3% (initiated with a Buy at Deutsche Bank)
- PSEC +1% (upgraded to Mkt Perform from Underperform at Raymond James)
- CIEN +0.8% (upgraded to Buy from Neutral at Citigroup)
- CHRW +0.7% (upgraded to Overweight from Equal-Weight at Stephens)